

Special Issue

Pediatric Sarcoma in the Era of Precision Genomics

Message from the Guest Editors

In this Special Issue, we focus on the use of precision genomics to interrogate biomarkers that are diagnostic, prognostic and/or predictors of therapeutic response in pediatric sarcoma. Functional validation of -OMICS data in relevant in-vitro and in-vivo models will contribute to our understanding of the molecular mechanisms involved in the pathogenesis of these sarcomas and help guide decisions on appropriate therapeutic interventions. Research articles and reviews focused on key pathways of dysregulation as well as preclinical modeling of pediatric sarcomas that evaluate aspects of tumor pathogenesis are encouraged. This includes studies focused on inter- and intra-genetic tumor heterogeneity, microenvironmental cues, metastatic potential, and therapeutic resistance mechanisms. Advancing our knowledge in these areas will be essential in our quest to discover improved treatment strategies and ultimately, a cure for aggressive sarcomas in children and AYA.

Guest Editors

Prof. Dr. Karen E. Pollok

1. Department of Pediatrics, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2. Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3. In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
5. Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Prof. Dr. Pankita H. Pandya

Division of Pediatric Hematology and Oncology, Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Deadline for manuscript submissions

closed (28 February 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/54828

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)